Diabetes Data Articles & Analysis
12 news found
Prior to this, Amit established the Digital Health function at Medtronic Diabetes, building the data science team to drive business and product strategy. ...
“Knowing people are motivated is a powerful insight that could lead a healthcare provider to recommend patients new and possibly more holistic diabetes management plans integrating diet, exercise, blood glucose testing, and taking advantage of apps to track and share health ...
ByLifeScan
This data will include new post-hoc analyses of FIDELITY, a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, as well as the design of the Phase II CONFIDENCE study, investigating simultaneous initial combination therapy with finerenone and an SGLT2-inhibitor in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Kerendia FIDELITY ...
ByBayer AG
Food and Drug Administration (FDA) for a label update for Kerendia™ (finerenone) to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The positive data from the pivotal Phase III FIGARO-DKD study demonstrated that finerenone significantly ...
ByBayer AG
The data was presented by Robert Ryder, M.D. of City Hospital, Birmingham, U.K. at the 82nd Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans on June 6, 2022. ...
The evaluation and treatment of diabetic foot ulcers and diabetic foot infections. Foot & Ankle Orthopaedics. 2018;3:3. doi:10.1177/2473011418788864 2.Sundararajan PP, Porter BM, Grant KA, et al. ...
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the results of the Company's recently completed Phase 1 clinical trial of pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH, will be presented in an oral presentation at the 82nd American Diabetes Association (ADA) Scientific ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes (T1D) and its Phase 1/2 trial of VX-880, a stem cell-derived, fully differentiated pancreatic islet cell replacement therapy, have been accepted for presentation during the American ...
Exploratory analysis of the FIGARO-DKD study with finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist, indicated a reduction in renal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), as seen in the FIDELIO-DKD study Analysis of the FIDELIO-DKD study highlighted that early reduction of urine albumin-to-creatinine ratio ...
ByBayer AG
Preclinical research and compassionate use data indicate 18-21 mg/kg will be the target effective dose for the expansion phase of the study. ...
Osel Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, announced today that City of Hope, a world-renowned independent cancer and diabetes research and treatment center, presented data from a Phase 1b trial showing that an LBP, CBM588 (Clostridium butyricum MIYAIRI 588® strain), plus ...
Kapural to share the significant data from the SENZA-PDN and the SENZA-NSRBP trials at NANS, reflecting our commitment to helping physicians treat underserved patient populations suffering from debilitating chronic pain. ...